Loading…
← CockpitCompetitor Analysis › IOVA Iovance Biotherapeutics IncOpen in the cockpit ↗

Iovance Biotherapeutics IncIOVACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops tumor-infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors, led by approved product Amtagvi.

Momentum leader 82
Mkt cap
$3.46B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$141M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-47.2 pp
WACC 9.4%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$7.48
1D-0.7%
1W-7.5%
1M-49.7%
3M-16.8%
6M+111.3%
YTD+174.0%
1Y+209.1%
ATR %10.9%
Beta1.59
52w lowhigh51.3% off high

What Iovance Biotherapeutics does

Develops tumor-infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors, led by approved product Amtagvi.

Earns from per-patient sales of Amtagvi, a one-time infusion made from the patient's own tumour tissue and shipped back to the hospital, so revenue depends on how many authorised treatment centres refer patients and how fast the manufacturing site can produce doses. It had no product sales before the 2024 approval.

Products and services

  • Amtagvi (lifileucel, melanoma)
  • TIL pipeline in other solid tumors

Customers

  • Oncology treatment centers
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Cell therapy for oncology

What could go right

  • Amtagvi commercial ramp in melanoma
  • Label expansion into additional tumor types

What could go wrong

  • Manufacturing complexity and capacity constraints
  • Reimbursement and adoption pace

Moat: narrow (IP / patents, regulatory licence, process know-how). First approved TIL therapy with complex manufacturing know-how, though the science is replicable.

Headquarters: San Carlos, California, US · Founded: 2007 · Employees: 975

Named competitors

Iovance Biotherapeutics at a glance

Size Iovance Biotherapeutics (IOVA) is a United States Health Care company (Biotechnology) with a market value of $3.46B, the 1438th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.48 on 18 Nov 2026.

Performance Over six months the shares gained 111.3%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 51.3% over the last twelve months (peer median +6.3%); the operating margin is -60.8% (peer median -3.8%).

Valuation It trades at 8.3× enterprise value to sales against a peer median of 12.7× (6th cheapest of 16).

Capital Return on invested capital runs 47.2 points below its cost of capital (9.4% WACC).

Short interest Short interest is 14.1% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030040021 May 202621 Aug 202618 Nov 2026IOVA 202Peer median 98
Six months, rebased to 100: Iovance Biotherapeutics against the median of its 20 peers (local-currency closes).

Iovance Biotherapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$379M$264M$164M$1.19M$0
Revenue growth—+61%+13,699%——
Gross profit$165M$54.4M$17.7M-$31.9M-$21.1M
EBITDA-$187M-$351M-$352M-$427M-$378M
Net income-$221M-$391M-$372M-$444M-$396M
Free cash flow-$216M-$336M-$364M-$384M-$313M
Capital expenditure$26.2M$33.8M$11.1M$22.3M$20.4M
Total debt$45.2M$49.4M$58.3M$75.9M$85.4M

Quarterly statements and history in the cockpit →

Iovance Biotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-40%-20%0%+20%600161IRONABCL6919ELVNRLAY603127TNGX002007VIRPXERSCRSP6696ADMATLXRUBICON2228IOVA6-month return →1-month return →
Up and to the right = strong over both horizons. Iovance Biotherapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×2,000×4,000×6,000×600161ABCL6919RLAY603127002007VIRPXERSCRSPTLXIOVARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Iovance Biotherapeutics is the large dot.

Iovance Biotherapeutics competitors and peer comparison

Head to head with its named competitors (IOVA vs BMY vs MRK vs REPL)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Iovance Biotherapeutics IOVA$3.46B+111%+51%-61%8.3×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Merck & MRK$340B+23%+5%18%5.7×8.3%
Replimune REPL$1.88B+321%n/an/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR$1.44B-7%+13%-7%2.3×n/a

How Iovance Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Iovance Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureIOVAPeer medianRank in peer set
1-month return-49.7%-4.9%lowest of 21
6-month return+111.3%-2.0%4th highest of 21
Distance from 52-week high-51.3%-31.6%4th lowest of 21
Revenue growth (TTM)+51.3%+6.3%2nd highest of 16
Operating margin-60.8%-3.8%7th lowest of 16
EV / Sales8.3×12.7×6th cheapest of 16
ROIC minus cost of capital-47.2 pp-10.0 pp3rd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%11.8×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a

Questions

Who are Iovance Biotherapeutics's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Instil Bio (private or unlisted), Adaptimmune (private or unlisted), Merck & Co (MRK), Replimune Group (REPL), Immunocore (IMCR). The cockpit's measured peer set (industry) also includes Beijing Tiantan Biological Products (600161.SS), Disc Medicine (IRON), AbCellera Biologics (ABCL), Caliway Biopharmaceuticals (6919.TW), Enliven Therapeutics (ELVN), Relay Therapeutics (RLAY).
Is Iovance Biotherapeutics expensive compared with its peers?
On ev / sales it trades at 8.3× against a peer median of 12.7×, 6th cheapest of 16 in its peer set.
How has Iovance Biotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +111.3% against -2.0% for the median peer; over one year +209.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.